Reviewer’s report

Title: Tomotherapy concomitant with Cetuximab, followed by Cetuximab as single-agent therapy for unresectable squamous cell carcinoma of the skin. A case report.

Version: 2 Date: 21 July 2014

Reviewer: Eve Maubec

Reviewer’s report:

Interest of radiation therapy and cetuximab has been demonstrated in head and neck tumors. This case report shows a good response with concomittant innovative radiation therapy (tomotherapy)and cetuximab is a patient with an advanced local disease. However several precisions/details are needed

Minor Essential Revisions

About the case report:
Has the complete response been confirmed by imaging evaluation?
How long was the follow up since treatment administration? 2 years? this has to be indicated in the case report and in the abstract. Indeed recurrences occur mainly during the 2 first years of follow up.

Other details
Line 126 and line 171: What means unresectable G1? which staging is used?
Size of the tumor?
What is the medical history of the patient?
Line 132: Is the cutaneous rash occurring at M5? this is not typical.
Line 148: However BCC and SCC differ. SCC can involve lymph nodes. It seems better to notify only SCC in this sentence.
L149: No trials has shown superiority of Mohs surgery compared to conventional surgery in SCC. So Mohs surgery is only an option and this requires to be taken in account.
L151 It seems better to say that chemotherapy "has often palliative indication". Indeed neoadjuvant chemotherapy followed by surgery can be curative (Sadek et al Cancer)

L 251 Only patients with locally advanced unresectable disease should be considered for radiation therapy and this has to be added.

Level of interest: An article of limited interest

Quality of written English: Acceptable
Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:
I declare that I have no competing interests' below